Actively Recruiting

Age: 18Years +
All Genders
NCT06257030

The AMARA (As Much As Reasonably Achievable) Study

Led by University Hospital of Patras · Updated on 2024-04-24

100

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Subjects with large inoperable liver tumors defined as at least 1 lesion larger than 5cm in maximum diameter. For the purposes of the present study, we define the AMARA principle in intensified regional TARE as a planned irradiated tumor dose \>200Gy by the partition model. The purpose of the study is to evaluate the safety and efficacy of Y90 high dose radioembolization for the management of large inoperable liver tumors. In addition, to correlate the safety and efficacy with the post-treatment dosimetry analysis (by MIM Software Inc) based on 90Y-PET/CT imaging.

CONDITIONS

Official Title

The AMARA (As Much As Reasonably Achievable) Study

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age >18 years
  • Both sexes eligible
  • Patients with primary or secondary liver tumors
  • Liver dominant disease
  • At least one lesion greater than 5.0 cm in maximum diameter
  • Life expectancy greater than 3 months
  • Future liver remnant (FLR) greater than 40% or more than 500 milliliters
  • Able to tolerate pre-treatment CT scan, digital subtraction angiography (DSA), and 99mTc-MAA infusion with SPECT/CT imaging
  • Able to schedule and tolerate post-treatment Y90 PET/CT imaging
  • Able to tolerate follow-up imaging with dynamic contrast CT liver phase or MRI with liver-specific contrast at 3, 6, 9 months, 1 year, 2 years, and 3 years
Not Eligible

You will not qualify if you...

  • Child Pugh score greater than B
  • Bilirubin level greater than 2 mg/dl
  • Albumin level less than 3.0
  • Central portal vein invasion
  • Multi-focal bilobar liver disease
  • Disseminated disease outside the liver
  • Lung shunt greater than 20% or estimated lung radiation dose greater than 20 Gy
  • Presence of extra-hepatic liver uptake
  • Unable to tolerate additional follow-up imaging

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Hospital of Patras

Pátrai, Achaia, Greece, 26500

Actively Recruiting

Loading map...

Research Team

K

Konstantinos Katsanos, Professor

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here